Clinical Trials Logo

Filter by:
NCT ID: NCT00515905 Completed - Clinical trials for Thoracic Surgery With One-lung Ventilation

One-lung Ventilation: Expression of Pulmonary Inflammatory Mediators

Start date: October 2004
Phase: N/A
Study type: Interventional

One-lung ventilation; organ protection; volatile anesthetics One-lung ventilation has become a common procedure for thoracoscopic surgery. Two hypothesis will be tested in this study: 1. Are inflammatory mediators increased in the re-ventilated lung after short-period pulmonary collapse? 2. Does Sevoflurane influence the production of inflammatory mediators in the re-inflated lung? Therefore, this study will elucidate the potential protective effect of a volatile anaesthetic (sevoflurane) on the production of inflammatory mediators by the respiratory compartment of the lung, i.e. the alveolar epithelium. - Trial with immunomodulatory product / biological

NCT ID: NCT00515801 Completed - Clinical trials for Diabetes Mellitus, Type 1

Sulfonylurea Effects on Glucagon Regulation During Hypoglycemia in Type 1 DM

Start date: June 2007
Phase: Phase 2/Phase 3
Study type: Interventional

We aim to demonstrate that oral administration of glibenclamide stimulates pancreatic glucagon secretion during hypoglycemia in insulin-deficient (C-peptide negative) patients with type 1 diabetes when compared to type 1 diabetic patients with residual insulin secretion (C-peptide positive).

NCT ID: NCT00515736 Terminated - Trauma Clinical Trials

Impact Of Antioxidant Micronutrients On Intensive Care Unit (ICU) Outcome

Etude-AOX
Start date: January 2003
Phase: Phase 3
Study type: Interventional

Critically ill patients are generally exposed to an increased oxidative stress, which is proportional to the severity of their condition. Endogenous antioxidant (AOX) defenses are depleted particularly in those patients with intense inflammatory response. The hypothesis tested is that early I:V: administration of a combination of AOX micronutrient supplements (Se, Zn, Vit C, Vit E, Vit B1) would improve clinical outcome in selected critically ill patients, by reinforcing the endogenous AOX defenses and reducing organ failure.

NCT ID: NCT00515151 Completed - Clinical trials for Bacterial Infections

Prevention of Catheter-Associated Infection With the Skin Disinfectant Octenidine Dihydrochloride

Start date: May 2002
Phase: Phase 4
Study type: Interventional

Health-care-acquired infections are of tremendous importance for patients, especially catheter-associated infections. More than 40% of all bloodstream infections are associated with central venous catheters (CVC; catheters which are inserted into a large vein near the heart). Of all patients that acquire such an infection 1% to 5% die as a result from it. The insertion site is the main source of contamination and infection. In general, bacteria of the skin are the cause of infection, especially in short-term CVCs (10-14 days). Therefore it is necessary to efficiently disinfect the skin for the preparation and care of CVC insertion sites. Several substances are used for disinfection. Alcohol-based disinfectants are mainly used in Central Europe, other preparations contain povidine-iodine or chlorhexidine. Alcoholic disinfectants have a rapid initial effect, chlorhexidine shows an additional remanent (longer lasting) effect. A further substance, octenidine dihydrochloride, also demonstrated a remanent effect in a pilot study with neurosurgical patients. The purpose of our study is to compare an alcohol-based disinfectant containing octenidine dihydrochloride with a pure alcoholic disinfectant regarding efficacy and tolerability in patients receiving a CVC for a minimum of 5 days.

NCT ID: NCT00514826 Completed - Clinical trials for Obstructive Sleep Apnea Syndrome

Study to Investigate Sleep Apnea Patients at Altitude

Start date: August 2007
Phase: N/A
Study type: Interventional

The purpose of the study is to investigate the effect of an altitude sojourn on patients with the obstructive sleep apnea syndrome

NCT ID: NCT00514514 Completed - Clinical trials for Kidney Transplantation

Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Calcineurin Inhibitor (CNI)-Free Regimen and a CNI-low Dose Regimen

Start date: July 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare renal function of immunosuppressive regimens with different relevance of the calcineurin inhibitor (CNI) cyclosporine: standard dose CNI, low dose CNI, CNI free in de novo kidney transplant patients after 12 months of therapy.

NCT ID: NCT00514384 Completed - Acute Heart Failure Clinical Trials

Serial Measurements of Biomarker in Patients With Acute Decompensated Heart Failure

Start date: February 2007
Phase: N/A
Study type: Observational

Evaluation of serial measurement of novel biomarker for diagnosis, prognosis or therapy monitoring in patients presenting with acute decompensated heart failure.

NCT ID: NCT00514228 Completed - Liver Cancer Clinical Trials

Sunitinib in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Start date: July 2007
Phase: Phase 2
Study type: Interventional

RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well sunitinib works in treating patients with liver cancer that cannot be removed by surgery.

NCT ID: NCT00513344 Completed - No Disease Clinical Trials

Efficacy of Polyphenols From Milk and Dark Chocolate

Start date: June 2008
Phase: N/A
Study type: Interventional

Dark chocolate is one of the richest sources of polyphenols though it has been hypothesised that the bioavailability and therefore probably the bioefficacy of epicatechin from milk chocolate was reduced compared to dark. This study is designed to compare milk and dark chocolate as a source of polyphenols with a control "chocolate" for improving a risk biomarker for vascular disease.

NCT ID: NCT00513266 Active, not recruiting - Colorectal Cancer Clinical Trials

Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by Surgery

Start date: June 2007
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, irinotecan, fluorouracil and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab and cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving combination chemotherapy together with monoclonal antibody therapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving combination chemotherapy together with monoclonal antibody therapy works in treating patients with advanced colorectal cancer with liver metastases or lung metastases that are potentially removable by surgery.